Current Projects
Immunotherapy stimulates the immune system and helps to induce effective anti-tumor activity. This could be achieved by stimulating dendritic cells, the key antigen presenting cells to capture tumor antigens that are released from tumor cells and cross present these antigens to T cells. However, poor clinical success is obtained with antigen alone. Thus the necessity of a therapeutic tool in combination with antigen is required to halt the tumor progression through effective identification of non-self antigens. This in vivo concept of therapeutic vaccination strategy is simple, inexpensive and labor saving compared to ex vivo dendritic cell vaccines. The aim of this project is to formulate a delivery system that will be a structurally modified PLGA nanoparticle based cancer vaccine coated with anti-CD205 antibody to selectively recognize dendritic cell receptors for delivering antigens to those cells. This active immunotherapy will be achieved by manipulating the immune response to boost cancer patients’ immune system, which will then become capable to recognize and eradicate cancer antigens in the body.